Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma

Journal of Clinical Pathology

Volumn 58, Issue 9, 2005, Pages 915-922

  Dlamini, Z ^a   Bhoola, K D ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KININ B 1 RECEPTOR; KININ B 2 RECEPTOR; PREKALLIKREIN; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; CELL INFILTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; GIANT CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAST CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GIANT CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; KALLIKREIN-KININ SYSTEM; MAST CELLS; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; TISSUE KALLIKREINS; UP-REGULATION;

EID: 24644457254     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.021444     Document Type: Article

References (40)

1. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
2. Clements J, Hooper J, Dong Y, et al. The expanded human kallikrein (KLK) gene family: genomic organization, tissue-specific expression and potential functions. Biol Chem 2001;382:5-14.
3. Roberts RA. Bradykinin receptors: characterisation, distribution and mechanisms of signal transduction. Prog Growth Factor Res 1989;1:237-252.
4. Roberts RA, Gullick WJ. Bradykinin receptor and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J Cell Sci 1989;94:527-35.
5. Bernitez-Bribiesca L, Martinez G, Ruiz M, et al. Proteinase activity in invasive cancer of the breast. Correlation with tumor progression. Arch Med Res 1995;26:S163-8.
6. Tsuboi R, Yamaguchi T, Kurita Y, et al. Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma and seborrheic keratosis. J Invest Dermatol 1988;6:869-72.
7. Werb Z, Vu TH, Rinkenberger JL, et al. Matrix-degrading proteases and angiogenesis during development and tumor formation. Acta Pathol Microbiol Immunol Scand 1999;107:11-18.
8. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodelling - cooperation of protease system and cell types. Acta Pathol Microbiol Immunol Scand 1999;107:120-7.
9. Parkin DM, Laara E, Muir CS. Estimates of the world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
10. Naidoo Y, Snyman C, Raidoo R, et al. Cellular visualization of tissue prokallikrein in human neutrophils and myelocytes. Br J Haematol 1999;105:599-612.
11. Angermann AR, Rahn HP, Hektor T, et al. Purification and characterization of human salivary-gland prokallikrein from recombinant baculovirus-infected insect cells. Eur J Biochem 1992;206:225-33.
12. Schachter M, Maranda B, Moriwaki C. Localisation of kallikrein in the coagulating and submandibular glands of the guinea-pig. J Histochem Cytochem 1978;26:318-21.
13. Henderson LM, Carlos D, Figueroa CD, et al. Assembly of the contact-phase factors on the surface of the human neutrophil membrane. Blood 1994;84:474-82.
14. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990;62:440-3.
15. Blot WJ, Devassa SS, Fraumeni JF. Continuing climb in rates of oesophageal adenocarcinoma: an update [letter]. JAMA 1993;270:1320.
16. Mosnier JF, Balique JB. Pleomorphic giant cell carcinoma of the esophagus with coexpression of cytokeratin and vimentin and neuroendocrine differentiation. Arch Pathol Lab Med 2004;124:135-8.
17. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003;60:64-9.
18. Elpeck G, Gelen T, Aksoy NH, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol 2001;54:940-4.
19. Tomita M, Matsuzaki Y, Edagawa M, et al. Association of mast cells with tumor angiogenesis in oesophageal squamous cell carcinoma. Dis Esophagus 2001;14:135-8.
20. Theoharis CT, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004;25:235-41.
21. Sawicki B, Kasacka I, Chyczewski I. Preliminary evaluation of mast cells and angiogenesis processes in experimental fibrosarcoma. Folia Histochem Cytobiol 2002;40:197-8.
22. Gallager SJ, Marshall JS, Hoskin DW. Human mast cells induce caspase-independent DNA fragmentation in leukemia T cells. Oncol Rep 2003;10:1019-23.
23. Diamandis EP, Yousef GM, Luo I, et al. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
24. Bhoola K, Ramsaroop R, Plendl J, et al. Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 2001;382:77-9.
25. Sawant S, Snyman C, Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and carcinomas. Int Immunopharmacol 2001;1:2063-80.
26. Uetsuji S, Yamamura M, Takai S, et al. Effect of aprotinin on metastasis of Lewis lung tumor in mice. Surg Today 1992;22:439-42.
27. Rehbock J, Bucinger P, Herman A, et al. Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. J Cancer Res Clin Oncol 1995;121:64-8.
28. Jones TH, Figueroa CD, Smith CM, et al. Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. J Endocrinol 134:149-54.
29. Clements J, Mukhtar A. Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology 1997;36:217-20.
30. Darson MF, Parcelli A, Roche P, et al. Kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
31. Kishi T, Soosaipillai A, Grass L, et al. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin Chem 2004;50:709-16.
32. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 2003;49:87-96.
33. Yousef GM, Polymeris ME, Grass L, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-65.
34. Kapadia C, Chang A, Soosaipillai A, et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 2003;49:77-86.
35. Hermann A, Buchinger P, Rehbock J. Visualization of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry. Biol Chem Hoppe Seyler 1995;376:365-70.
36. Hembree TN, Leeb-Lundberg LM. Regulation of bradykinin B2 receptors by the ras oncogene: evidence for multiple mechanisms. J Cell Physiol 1996;169:248-55.
37. Parries G, Hoebel R, Racker E. Opposing effects of ras oncogene on growth factor-stimulated phosphoinositide hydrolysis: desensitization to platelet-derived growth factor and enhanced sensitivity to bradykinin. Proc Natl Acad Sci U S A 1987;84:2648-52.
38. Hargreaves KM, Troullos ES, Dionne RA, et al. Bradykinin is increased during acute and chronic inflammation: therapeutic implications. Clin Pharmacol Ther 1988;44:613-21.
39. Stuardo M, Gonzalez CB, Nualart F, et al. Stimulated human neutrophils form biologically active kinin peptides from high and low molecular weight kininogens. J Leukoc Biol 2004;75:631-40.
40. Borkowski JA, Ransom RW, Seabrook GR, et al. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 1995;270:13706-10.